Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication

Assay and Drug Development Technologies

Volumn 13, Issue 10, 2015, Pages 638-649

  Perwitasari, Olivia ^a   Yan, Xiuzhen ^a   O'Donnell, Jason ^a   Johnson, Scott ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DINACICLIB; FLAVOPIRIDOL; PHOSPHOTRANSFERASE INHIBITOR; PIK 75; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

A549 CELL LINE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H7N9); NONHUMAN; VIRUS REPLICATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; PROCEDURES; SAFETY;

ANTIVIRAL AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H7N9 SUBTYPE; PROTEIN KINASE INHIBITORS; SAFETY; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84952316397     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.0003.drrr     Document Type: Article

References (65)

1. Fiore AE, Uyeki TM, Broder K, et al. Prevention, and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1-62
2. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005; 53: 1-48
3. Podewils LJ, Liedtke LA, McDonald LC, et al. A national survey of severe influenza-associated complications among children, and adults, 2003-2004. Clin Infect Dis 2005; 40: 1693-1696
4. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-1897
5. Krammer F, Palese P. Universal influenza virus vaccines: need for clinical trials. Nat Immunol 2014; 15: 3-5
6. Palese P. Influenza: old, and new threats. Nat Med 2004; 10(12 Suppl): S82-S87
7. McElhaney JE. The unmet need in the elderly: Designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1): S10-S25
8. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the united states. JAMA 2004; 292: 1333-1340
9. Hayden FG, Hay AJ. Emergence, and transmission of influenza A viruses resistant to amantadine, and rimantadine. Curr Topics Microbiol Immunol 1992; 176: 119-130
10. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment, and chemoprophylaxis of influenza- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-24
11. Chong CR, Sullivan DJ, Jr. New uses for old drugs. Nature 2007; 448: 645-646
12. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185
13. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research, and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. PharmacoEconomics 1995; 7: 152-169
14. Collins FS. Mining for therapeutic gold. Nat Rev Drug Discov 2011; 10: 397
15. Perwitasari O, Bakre A, Tompkins SM, Tripp RA. siRNA genome screening approaches to therapeutic drug repositioning. Pharmaceuticals 2013; 6: 124-160
16. Hao L, Sakurai A, Watanabe T, et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008; 454: 890-893
17. Karlas A, Machuy N, Shin Y, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463: 818-822
18. Konig R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus replication. Nature 2010; 463: 813-817
19. Meliopoulos VA, Andersen LE, Brooks P, et al. MicroRNA regulation of human protease genes essential for influenza virus replication. PloS One 2012; 7: e37169
20. Meliopoulos VA, Andersen LE, Birrer KF, et al. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J 2012; 26: 1372-1386
21. Perwitasari O, Yan X, Johnson S, et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza A virus strategy. Antimicrob Agents Chemother 2013; 57: 475-483
22. Lee SM-Y, Yen H-L: Targeting the host or the virus: Current, and novel concepts for antiviral approaches against influenza virus infection. Antivir Res 2012; 96: 391-404
23. Kumar N, Liang Y, Parslow TG, Liang Y. Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication. J Virol 2011; 85: 2818-2827
24. Ehrhardt C, Wolff T, Pleschka S, et al. Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 2007; 81: 3058-3067
25. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity 2013; 38: 855-869
26. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (New York N.Y.). 2002; 298: 1912-1934
27. Cohen P. Protein kinases- the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-315
28. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 727-730
29. Kumar CC, Madison V. Drugs targeted against protein kinases. Expert Opin Emerg Drugs 2001; 6: 303-315
30. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science (New York N.Y.) 2004; 303: 1800-1805
31. Vogel U, Kunerl M, Scholtissek C. Influenza A virus late mRNAs are specifically retained in the nucleus in the presence of a methyltransferase or a protein kinase inhibitor. Virology 1994; 198: 227-233
32. Sasaki Y, Kakisaka M, Chutiwitoonchai N, et al. Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity. Biochem Biophys Res Commun 2014; 450: 49-54
33. Martinez-Gil L, Alamares-Sapuay JG, Ramana Reddy MV, Goff PH, Premkumar Reddy E, Palese P. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Antivir Res 2013; 100: 29-37
34. Pleschka S, Wolff T, Ehrhardt C, et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001; 3: 301-305
35. Hirata N, Suizu F, Matsuda-Lennikov M, Edamura T, Bala J, Noguchi M. Inhibition of Akt kinase activity suppresses entry, and replication of influenza virus. Biochem Biophys Res Commun 2014; 450: 891-898
36. Woolcock PR. Avian influenza virus isolation, and propagation in chicken eggs. Methods Mol Biol (Clifton N.J.) 2008; 436: 35-46
37. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938; 27: 493-497
38. Birmingham A, Selfors LM, Forster T, et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 2009; 6: 569-575
39. Jones RE, Zheng W, McKew JC, Chen CZ. An alternative direct compound dispensing method using the HP D300 digital dispenser. J Lab Autom 2013; 18: 367-374
40. Szretter KJ, Balish AL, Katz JM. Influenza: Propagation, Quantification, and Storage. Curr Protoc Microbiol 2006: Chapter 15: Unit 15G.1
41. Prichard MN, Shipman C, Jr. Analysis of combinations of antiviral drugs, and design of effective multidrug therapies. Antivir Ther 1996; 1: 9-20
42. Wang S, Zhang J, Ye X: [Protein kinase inhibitor flavopiridol inhibits the replication of influenza virus in vitro]. Wei Sheng Wu Xue Bao 2012; 52: 1137-1142
43. Stewart CE, Randall RE, Adamson CS. Inhibitors of the interferon response enhance virus replication in vitro. PloS One 2014; 9: e112014
44. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate, and Zanamivir. Antimicrob Agents Chemother 2002; 46: 3809-3816
45. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antivir Res 2013; 98: 174-185
46. Zhang J, Li G, Ye X. Cyclin T1/CDK9 interacts with influenza A virus polymerase, and facilitates its association with cellular RNA polymerase II. J Virol 2010; 84: 12619-12627
47. Hale BG, Knebel A, Botting CH, et al. CDK/ERK-mediated phosphorylation of the human influenza A virus NS1 protein at threonine-215. Virology 2009; 383: 6-11
48. Perwitasari O, Torrecilhas AC, Yan X, et al. Targeting cell division cycle 25 homolog B to regulate influenza virus replication. J Virol 2013; 87: 13775-13784
49. Ehrhardt C, Marjuki H, Wolff T, et al. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection, and host cell defence. Cell Microbiol 2006; 8: 1336-1348
50. Planz O. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antivir Res 2013; 98: 457-468
51. Shin Y-K, Liu Q, Tikoo SK, Babiuk LA, Zhou Y. Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J Gener Virol 2007; 88: 942-950
52. Acosta YY, Montes-Casado M, Aragoneses-Fenoll L, Dianzani U, Portoles P, Rojo JM. Suppression of CD4 + T lymphocyte activation in vitro, and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75. Int J Immunopathol Pharmacol 2014; 27: 53-67
53. Duong HQ, Yi YW, Kang HJ, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol 2014; 44: 959-969
54. Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility, and metastasis. Oncogene 2012; 31: 706-715
55. Thomas D, Powell JA, Vergez F, et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling, and Cdk9-mediated Mcl-1 transcription. Blood 2013; 122: 738-748
56. Fabre C, Gobbi M, Ezzili C, et al. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 2014; 74: 1057-1064
57. Gojo I, Sadowska M, Walker A, et al. Clinical, and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 2013; 72: 897-908
58. Mita MM, Joy AA, Mita A, et al. Randomized phase II trial of the cyclindependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014; 14: 169-176
59. Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, doseescalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013; 11: 259
60. Ang C, O?Reilly EM, Carvajal RD, et al. A nonrandomized, phase II study of sequential irinotecan, and flavopiridol in patients with advanced hepatocellular carcinoma. Gastrointest Cancer Res 2012; 5: 185-189
61. Bible KC, Peethambaram PP, Oberg AL, et al. A phase 2 trial of flavopiridol (Alvocidib), and cisplatin in platin-resistant ovarian, and primary peritoneal carcinoma: MC0261. Gynecol Oncol 2012; 127: 55-62
62. Bose P, Perkins EB, Honeycut C, et al. Phase I trial of the combination of flavopiridol, and imatinib mesylate in patients with Bcr-Abl + hematological malignancies. Cancer Chemother Pharmacol 2012; 69: 1657-1667
63. Hofmeister CC, Poi M, Bowers MA, et al. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol 2014; 73: 249-257
64. Karp JE, Garrett-Mayer E, Estey EH, et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 2012; 97: 1736-1742
65. Luke JJ, D?Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations, and results of a phase I dose-escalation clinical trial. Clin Cancer Res 2012; 18: 2638-2647